Zoetis is a global leader in animal health, dedicated to providing innovative products and solutions that enhance the health and well-being of animals
The company develops a broad range of medicines, vaccines, and diagnostic tools for both livestock and companion animals, supporting veterinarians and producers in improving animal health through science-based products. With a commitment to advancing veterinary medicine and sustainability, Zoetis works to ensure safe and sustainable food supply chains while enhancing the quality of life for pets and livestock around the world.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQCORT) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSEBMY) and the best and worst performers in the branded pharmaceuticals industry.
Over the past six months, Zoetis’s shares (currently trading at $166) have posted a disappointing 9.6% loss, well below the S&P 500’s 7.6% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry has tumbled by 1.7% over the last six months. This drawdown is a stark contrast from the S&P 500’s 9% gain.
Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data.
Shares of animal health company Zoetis (NYSEZTS)
fell 10.6% in the morning session after the company reported disappointing fourth-quarter results: its full-year EPS and revenue guidance fell short of Wall Street's estimates. Revenue grew 5% year over year, as weakness in livestock sales, which declined due to the divestiture of certain products, was partly offset by strength in the companion animal segment. Looking ahead, Zoetis expects 6% to 8% organic operational revenue growth, but foreign exchange pressures and ongoing challenges could create headwinds. Overall, this quarter could have been better.
Animal health company Zoetis (NYSEZTS) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.7% year on year to $2.32 billion. On the other hand, the company’s full-year revenue guidance of $9.3 billion at the midpoint came in 2.8% below analysts’ estimates. Its non-GAAP profit of $1.40 per share was 4.7% above analysts’ consensus estimates.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
